The patient with inflammatory bowel disease (IBD), either Crohn's disease or ulcerative colitis, faces specific challenges in the management of obesity. These include alterations in small and large bowel function contributing to maldigestion and malabsorption of both nutrients and oral medications and the fundamental changes in intestinal function occurring with bariatric surgery. Furthermore, there may be IBD-related abnormalities influencing hepatic function and drug metabolism. All of these will impact on the treatment of obesity. In terms of the treatment of IBD, obesity and its associated GI complications play a role in terms of drug distribution, and the emerging literature indicates an important impact of adipokines on the intestinal microbiome and intestinal inflammation. Furthermore, prior bariatric surgery poses additional challenges in terms of oral drug absorption and will influence the choice of bariatric operation.

CME/CE Expiration Date: 4/26/27

*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.